Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV)

Q: What does CUSIP 28623U101 represent in this 13F holders report?

CUSIP 28623U101 is the security identifier for ELEV - Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share used to aggregate holder disclosures.

Q: How many institutions held ELEV - Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share in Q1 2023?

27 institutional investors reported ELEV - Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share for Q1 2023. Use the holders table for investor-level position and value details.

CUSIP: 28623U101

Q1 2023 13F Holders as of 31 Mar 2023

Type / Class: Equity / Common Stock, par value $0.0001 per share
Shares outstanding: 62,337,402
Total 13F shares: 16,241,361
Share change: +1,817,583
Total reported value: $30,858,572
Price per share: $1.90
Number of holders: 27
Value change: +$3,765,785
Number of buys: 14
Number of sells: 9

Quarterly Holders Quick Answers

What is CUSIP 28623U101?
CUSIP 28623U101 identifies ELEV - Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2023
Previous quarter: Q4 2022

Recent filing periods for CUSIP 28623U101:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of ELEV - Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) as of Q1 2023

As of 31 Mar 2023, Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) was held by 27 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 16,241,361 shares. The largest 10 holders included Aisling Capital Management LP, Qiming U.S. Ventures Management, LLC, BVF INC/IL, Cormorant Asset Management, LP, venBio Partners LLC, TANG CAPITAL MANAGEMENT LLC, Sio Capital Management, LLC, Samsara BioCapital, LLC, VANGUARD GROUP INC, and Walleye Capital LLC. This page lists 27 institutional shareholders reporting positions in this security for the Q1 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2023 vs Q4 2022 Across Filers

Q4 2022 holders

Q1 2023 holders

Holder diff

Investor	Q4 2022 Shares	Q1 2023 Shares	Share Diff	Share Chg %	Q4 2022 Value $	Q1 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.